High-affinity CD4 and CD8 T cell clones have been shown to be more susceptible to DHODH inhibition, and individual T cell clones are eliminated from the TCR Vβ repertoire of patients with MS within weeks of initial teriflunomide treatment (10). Here, CD8A is linked to myeloid sarcoma.